On January 7, 2019, the U.S. Supreme Court declined to review an appeals court decision that authorizes private individuals to sue drug manufacturers for government-contracting fraud based on technical violations of federal regulations—even if the FDA approved the drugs and the government continued to purchase them after investigating the allegations. While the denial was a disappointment for WLF (which filed a brief urging review), the outcome of the case was favorable. In response to WLF’s brief, the Supreme Court asked the federal government to weigh in—and it responded by telling the Court that the suit was unwarranted and that it would move for dismissal. WLF’s brief argued that the appeals court’s decision facilitates the filing of unwarranted claims under the False Claims Act (FCA) against government contractors. It argued that the government’s response to the whistleblower’s fraud claims demonstrated that any regulatory violation was not “material,” an FCA prerequisite.